No abstract

The present study demonstrates that knowledge about national guideline and reimbursement policies, training programs, perceptions about effectiveness and safety of influenza vaccine increase HCWs' willingness to recommend the influenza vaccination to diabetic patients. These measures should be taken to ensure HCWs' role in the administration of influenza vaccination among diabetic patients.

No abstract

Neonatal hypoxic-ischemic (HI) brain injury is a devastating disease that often leads to death and detrimental neurological deficits. The present study was designed to evaluate the ability of metformin to provide neuroprotection in a model of neonatal hypoxic-ischemic brain injury and to study the associated molecular mechanisms behind these protective effects. Here, we found that metformin treatment remarkably attenuated brain infarct volumes and brain edema at 24 h after HI injury, and the neuroprotection of metformin was associated with inhibition of neuronal apoptosis, suppression of the neuroinflammation and amelioration of the blood brain barrier breakdown. Additionally, metformin treatment conferred long-term protective against brain damage at 7 d after HI injury. Our study indicates that metformin treatment protects against neonatal hypoxic-ischemic brain injury and thus has potential as a therapy for this disease.

Wound healing, especially for diabetic wounds, is a lengthy and complicated process involving interactions and responses at the protein, cell, and tissue levels. Loading of growth factors into a hydrogel to construct a sustained‐release system is considered a promising approach to improve wound healing. The present study investigates the effect of thermosensitive heparin‐poloxamer (HP) hydrogel–encapsulated recombinant human fibroblast growth factor 21 (rhFGF21) on wound healing in mice with streptozotocin‐induced diabetes mellitus. First, we studied the in vitro release of rhFGF21 from the rhFGF21‐HP coacervate. The results showed that HP might control the release of rhFGF21. Next, we examined the effect of rhFGF21‐HP on skin wound healing in diabetic mice. Our data showed that rhFGF21‐HP significantly improved wound closure; promoted granulation, collagen deposition, and re‐epithelialization; and enhanced the expression of CD31. Moreover, rhFGF21‐HP had obvious advantages in diabetic wound healing. Therefore, the results suggest that the rhFGF21‐HP hydrogel polymer plays an important role in skin wound healing. This work provides a suitable sustained‐release delivery system that can continuously release rhFGF21 and presents a promising therapeutic strategy for wound healing in patients with diabetes.—Liu, H., Zhao, Y., Zou, Y., Huang, W., Zhu, L., Liu, F., Wang, D., Guo, K., Hu, J., Chen, J., Ye, L., Li, X., Lin, L. Heparin‐poloxamer hydrogel–encapsulated rhFGF21 enhances wound healing in diabetic mice. FASEB J. 33, 9858–9870 (2019). http://www.fasebj.org